Project Background
While high drug prices are widely criticized, few accessible research publications have directly linked pharmaceutical industry practices to broader socioeconomic inequality. From pay-for-delay schemes and patent abuse to price gouging and regulatory capture, market dynamics in the pharma industry often deepen disparities in health and wealth. This initiative addresses that gap by producing research grounded in economic data, legal analysis, and health equity frameworks. The goal is to make complex systems understandable and actionable—especially for policymakers, students, and advocacy groups.
The Research Publications Initiative aims to publish original, data-driven studies exploring the connection between pharmaceutical pricing, market concentration, and ecenomics. The project seeks to influence policy, inform public debate, and expose systemic drivers of drug pricing injustice through high impact, accessible research.
Objectives
Publish 3–5 original research papers or review papers connecting pharma pricing strategies to economic inequality
Key Features Delivered
lInterdisciplinary Approach: Combine economics, public health, law, and ethics to present a holistic view of the issue.
Open Access Distribution: Publish on platforms that allow public access—no paywalls or exclusive publishing rights.
Our Approach
Identify 3–5 key research topics such as:
The role of patent extension in blocking generics
Pharmaceutical lobbying and pricing behavior
Impact of high-cost drugs on uninsured or underinsured populations
Correlation between pharmaceutical monopolies and income inequality
Tthe impact of the finance sector on pharma acountability
Results
3–5 research papers published on pharma pricing and inequality
2,000+ online reads or downloads across platforms
Prev Project
